<DOC>
	<DOCNO>NCT02076399</DOCNO>
	<brief_summary>The purpose study determine whether fostamatinib safe effective treatment persistent/chronic Immune Thrombocytopenic Purpura ( ITP ) .</brief_summary>
	<brief_title>A Efficacy Safety Study R935788 Treatment Persistent/Chronic Immune Thrombocytopenic Purpura ( ITP )</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<criteria>Clinical diagnosis persistent/chronic ITP least 3 month . Average platelet count &lt; 30,000/ÂµL ( none &gt; 35,000 unless result rescue therapy ) least 3 qualify count Clinical diagnosis autoimmune hemolytic anemia Uncontrolled poorly control hypertension History coagulopathy include prothrombotic condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Persistent Immune Thrombocytopenic Purpura</keyword>
	<keyword>Chronic Immune Thrombocytopenic Purpura</keyword>
</DOC>